Therefore, angiogenic inducers such as basic fibroblast growth factor and vascular endothelial growth factor (VEGF) have been used for neovascularization of ischemic diseases, 6) wound healing, and tissue regeneration. 7) Panax ginseng C. A. MAYER is well known as the most important herbal medicine in traditional eastern Asia for more than 2000 years and is now one of the most extensively used botanical products in the world. 8, 9) Among the several kinds of Panax ginseng products, Korean red ginseng has the most potent multiple pharmacological actions for treating various human diseases including cardiovascular diseases, rheumatoid arthritis, and diabetes mellitus. 10, 11) The major active ingredients of ginseng are the triterpene glycosides known as ginsenosides, which have been studied extensively for their pharmacological effects. Ambiguously, pure ginsenosides have been reported to promote wound healing 11) and inhibit tumor growth 12) through opposing effects on angiogenesis. 13) Presently, the use of whole ginseng products such as steamed ginseng (Korean red ginseng), ginseng powder, and ginseng extract as alternative medicine have seen resurgence in use in the United States and Europe as well as Asian countries. However, the angiogenic effects of Korean red ginseng water extract (KRGE) and its underlying mechanisms have not been clearly studied in vitro and in vivo. It has been shown that KRGE and its saponins possess multiple pharmacological actions for treating various diseases including wound healing, 14) liver regeneration, 15) cerebral ischemia, 16) and hypertension, 17) which are associated with endothelial cell dysfunction or dysregulation of angiogenesis. We here investigated the effect of KRGE on angiogenesis and its intracellular signal pathway in human umbilical vein endothelial cells (HUVECs). Our results show that KRGE stimulates angiogenesis in vitro and in vivo through activation of the phosphatidylinositol 3-kinase (PI3K)/Aktdependent ERK1/2 and eNOS pathways. Cell Culture and Animals HUVECs were isolated from human umbilical cord veins by collagenase treatment as described previously 19) and used in passages 3-7. The cells were grown in M199 medium (Invitrogen, Carlsbad, CA, U.S.A.) supplemented with 20% fetal bovine serum (FBS; Hyclone, Logan, UT, U.S.A.), 100 units/ml penicillin, 100 mg/ml streptomycin, 3 ng/ml basic fibroblast growth factor (Upstate Biotechnology, Lake Placid, NY, U.S.A.), and 5 units/ml heparin at 37°C within humidified 5% CO 2 /95% air. Male ICR mice (6-8 weeks old) and Sprague-Dawley rats (6 weeks old) were obtained from Orient (Sungnam, Korea) and maintained at the specific pathogen-free housing facility of the School of Medicine, Kangwon National University (Chunchon, Korea). All procedures performed on these animals were in accordance with the guidelines of the University Animal Care and Use Committee.
MATERIALS AND METHODS

Reagents and Chemicals
Proliferation Assay Cells were seeded at a density of 2ϫ10 4 cells per well in 24-well plates. Proliferation was determined 48 h after KRGE or VEGF treatment using colorimetry based on the uptake of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt (MTT) by viable cells. In brief, MTT solution (0.5 mg/ml) was added to the cells and incubated at 37°C to allow cleavage of the tetrazolium ring by mitochondrial dehydrogenases and the formation of blue formazan crystals. After 2 h, the residual MTT was carefully removed and the crystals were dissolved by incubation with isopropanol for 10 min. The plates were shaken for 5 min and the absorbance at 570 nm was measured by spectrophotometry. The optical density of untreated cells represented 100% viable cells and background color formation of MTT with PBS added to an empty plate. 19) Chemotaxis Assay Chemotactic motility of HUVECs was assayed using Transwell with 6.5 mm diameter polycarbonate filters (8 mm pore size). The lower surface of the filter was coated with 10 mg of gelatin. Fresh M199 media (1% FBS) containing KRGE or VEGF was placed in the lower wells. HUVECs were trypsinized and suspended at a final concentration of 1ϫ10 6 cells/ml in M199 containing 1% FBS. Inhibitors were incubated with the cells for 30 min at room temperature before seeding. One hundred microliters of the cell suspension was loaded into each of the upper wells. The chamber was incubated at 37°C for 4 h. Cells were fixed and stained with hematoxylin and eosin. Non-migrating cells on the upper surface of the filter were removed by wiping with a cotton swab and chemotaxis was quantified by counting the cells that migrated to the lower side of the filter with an optical microscope. 19) Ten random fields were counted for each assay.
Tube Formation Assay Growth factor-reduced Matrigel (250 ml, 10 mg protein/ml) was pipetted into a 24-well plate and polymerized for 30 min at 37°C. HUVECs incubated in M199 containing 1% FBS for 6 h were harvested after trypsin treatment, resuspended in M199, and plated onto the layer of Matrigel at a density of 2ϫ10 5 cells/well, followed by the addition of KRGE or VEGF. Matrigel cultures were incubated at 37°C. After 20 h, tube formation was assayed by a microscope. 19) Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis RT-PCR assay was performed as previously described. 19) Briefly, total RNAs were obtained from HUVECs using the Trizol Reagent kit (Invitrogen, Carlsbad, CA, U.S.A.). Five micrograms of total RNA was reverse transcribed and the resultant cDNAs were amplified by PCR using a primer pair specific for VEGF. PCR was performed in 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 0.2 mM dNTPs, 2.5 units of Taq DNA polymerase, and 0.1 mM of each primer for VEGF or actin. The reaction mixture was heated at 94°C for 1 min, annealed at 55°C for 2 min, and extended at 72°C for 3 min for 30 repetitive cycles. The primers used were 5Ј-GGCCTCCGAAACCAT-GAACTTTCTGCT-3Ј (sense) and 5Ј-CCTCCTGCCCGG-CTCACCGC-3Ј (antisense) for VEGF. b-Actin was used as an internal control.
Angiogenesis Assay Angiogenic activity of KRGE was determined by aortic ring sprouting assay and intravital microscopy as previously described. 19, 20) For the aortic ring sprouting assay, plates (96-well) were coated with 60 ml Matrigel, and aortic rings isolated from Sprague-Dawley rats were placed in the wells and cultured with 100 ml human endothelial serum-free medium (Invitrogen, Carlsbad, CA, U.S.A.) containing KRGE or VEGF for 6 d. Microvessel outgrowth was photographed under a phase microscope. For intravital imaging, male ICR mice were anesthetized and abdominal wall windows were implanted. Growth-factor-reduced Matrigel containing KRGE or VEGF was put into the window inner space. After 4 d, animals were anesthetized and intravenously injected with 50 ml of 25 mg/ml fluorescein isothiocyanate-labeled dextran (MW 250000) via tail vein. Neovessel formation was photographed under a Zeiss Axiovert 200M microscope (Carl Ziess, Gottingen, Germany). The assays were scored from 0 (least positive) to 5 (most positive) in a double-blind manner.
Western Blotting HUVECs were scraped off the plates and lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet-P40, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate). Cell lysates (50 mg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinyldifluoride membrane. Membranes were incubated with antibodies against target proteins for 2 h. After washing twice, membranes were incubated with the corresponding horseradish peroxidase-conjugated secondary antibody, and signal intensities of target proteins were detected by the enhanced chemiluminescence system (Amersham Biosciences, Piscataway, NJ, U.S.A.) as previously described. 19) Nitric Oxide (NO) Measurement The NO level in HUVECs was measured in situ by using DAF-FM diacetate (Molecular Probes Inc.). 19) Briefly, 4 h after KRGE treatment, cells were washed twice with serum-free medium and then incubated with 5 mM DAF-FM diacetate for 1 h at 37°C. After the excess probe was removed, cells were incubated for an additional 20 min to allow for complete de-esterification of the intracellular DAF-FM diacetate to the non-permeable and non-fluorescent DAF-FM, which is converted to the highly fluorescent triazol form in the presence of NO and oxygen. The fluorescence images were captured from at least 10 randomly selected cells per dish using a confocal laser microscope. The relative levels of intracellular NO were determined from the fluorescence intensity of DAF-FM/NO adduct.
Statistical Analysis The data are presented as meansϮ standard error (S.E.) or as percentages of the meanϮS.E. from at least three different experiments performed in triplicate. Statistical evaluation of the results was performed by ANOVA followed by Bonferroni multiple comparisons test, or where applicable, by Student's t test. pϽ0.05 was considered statistically significant.
RESULTS
KRGE Induces Proliferation, Migration, and Tube Formation of HUVECs
We first examined whether KRGE would regulate endothelial cell angiogenesis, which requires the precise coordination of multiple steps such as endothelial cell proliferation, migration, and tube formation. When HUVECs were treated with different concentrations (0.01-1 mg/ml) of KRGE in M199 with 5% FBS for 48 h, KRGE stimulated endothelial cell proliferation in a dose-dependent manner, with a 1.5-fold increase at 500 mg/ml (Fig. 1A) . The cell proliferation activity of KRGE (500 mg/ml) treated cells was comparable to that of VEGF (10 ng/ml) treated cells (Fig. 1B) . The effect of KRGE on the chemotactic motility of HUVECs was also measured by using a Transwell assay. The extract stimulated the chemotactic motility of HUVECs in a dose-dependent manner with near maximal activity at 500 mg/ml (Fig. 1C) . The migratory activity at 1 mg/ml KRGE was 1.6-fold higher than the control. We next investigated the effect of KRGE on tube formation of HUVECs by using a 2D Matrigel assay. KRGE stimulated tube formation at a concentration as low as 10 mg/ml, and higher concentrations increased tube formation in a dose-dependent manner with near maximal activity (1.7 fold) at 100 mg/ml (Fig. 1D) . These results indicate that KRGE possesses angiogenic activity in an in vitro human endothelial cell culture system. KRGE Induces Angiogenesis ex Vivo and in Vivo To further investigate whether KRGE regulates in vitro angiogenesis, we examined the effect of KRGE on angiogenesis ex vivo and in vivo by rat aortic ring sprouting assay and intravital microscopy. Treatment with KRGE resulted in about a 13-fold increase in microvessel sprouting in the cut edge of rat aortic rings compared with control (0.23Ϯ0.37 vs. 3.31Ϯ0.68) ( Fig. 2A) , and this angiogenic effect of KRGE at 500 mg/ml was comparable to that of the optimal concentration of the well-known angiogenic factor VEGF (10 ng/ml) (Fig. 2B) . Angiogenic activity of KRGE was also observed in a mouse model by intravital microscopy. Injection with KRGE resulted in a significant number of newly formed blood vessels compared with control (Fig. 2C) . This angiogenic activity of KRGE was comparable to that induced by VEGF (Fig. 2D) . Taken together, these results provide clear evidence that KRGE can promote angiogenesis ex vivo and in vivo.
KRGE Induces Angiogenesis without Affecting VEGF Expression
The biological activity of endogenous angiogenic factors may be the result of either their direct action on endothelial cells or through the induction of other genes, including VEGF, which is a selective mitogen and motogen for endothelial cells, leading to angiogenesis. 21) To test the possi- bility that the effect of KRGE on angiogenesis is mediated through the induction of VEGF expression, the expression of VEGF by KRGE in endothelial cells was assessed by RT-PCR analysis. As previously reported, 21) TNF-a treatment significantly increased VEGF mRNA expression in cultured HUVECs, whereas KRGE did not affect the levels of VEGF mRNA in human endothelial cells compared with control (Fig. 3A) . To re-confirm the results of RT-PCR analysis, we examined the effect of VEGF-neutralizing antibody on the angiogenic activity of KRGE. Treatment with VEGF-neutralizing antibody significantly reduced VEGF-induced endothelial cell proliferation, but did not affect KRGE-induced proliferation (Fig. 3B) . These results indicate that KRGE-induced angiogenesis is not caused by the induction of VEGF expression, suggesting that KRGE may act as a direct angiogenic modulator in endothelial cells.
KRGE Activates ERK, Akt, and eNOS in HUVECs
The phosphorylation of ERK, Akt, and eNOS are important signaling events for the proliferation, migration, and morphogenesis of endothelial cells induced by various angiogenic factors. 13, 19, 20) Therefore, we examined whether KRGE regulates the phosphorylation of ERK, Akt, and eNOS, as determined by Western blot analysis using specific antibodies against their phosphorylated forms. Treatment of HUVECs with KRGE increased ERK1/2 phosphorylation in dose-and time-dependent manners (Fig. 4A) , and maximal activation was observed after 20-30 min of KRGE treatment and declined thereafter (data not shown). In addition, KRGE treatment also elevated the phosphorylation of Akt and eNOS in a time-dependent manner (Fig. 4B) . Angiogenic factors including VEGF activate Akt-dependent eNOS phosphorylation and leads to an increase in NO production, which potentiates angiogenesis. 19, 20) We next determined NO production in HUVECs treated with KRGE in the presence or absence of the NOS inhibitor NMA, as measured by fluorescent microscopy using a NO-sensitive fluorescent probe. KRGE increased NO production in HUVECs compared with control, and this increase was significantly abolished by the addition of NMA (Fig. 4C) . These results indicate that activation of Akt, ERK, and eNOS as well as elevation of NO production may be involved in KRGE-mediated angiogenesis of HUVECs.
KRGE-Induced Angiogenesis Is Mediated via the PI3K/Akt-Dependent MEK/ERK and eNOS/NO Signaling Pathways
To investigate the functional involvement of Akt, ERK, and eNOS in the KRGE-mediated angiogenic signal cascade, we examined the effect of the PI3K inhibitor wortmannin, the NOS inhibitor NMA, and the MEK inhibitor PD98059 on KRGE-dependent phosphorylation events. The KRGE-mediated increase in ERK phosphorylation was abolished by treatment with wortmannin and PD98059, but was partially suppressed by the addition of NMA (Fig. 5A) . Phosphorylation of Akt and eNOS by KRGE was inhibited to the control level by wortmannin, but not affected by NMA and PD98059 (Fig. 5A) . These results suggest that ERK1/2 phosphorylation is directly regulated by PI3K/Akt activation, probably via MEK activation, and partially controlled by eNOS-dependent NO production in KRGE-treated HUVECs. We further examined the involvement of ERK, Akt, and eNOS in KRGE-mediated angiogenic processes of HUVECs using these pharmacological inhibitors. KRGE-mediated increases in endothelial cell proliferation and migration were almost completely blocked by wortmannin and PD98059, but were partially suppressed by NMA (Figs. 5B, C) . However, KRGE-induced tube formation was nearly abolished by all three inhibitors (Fig. 5D) . These results suggest that the KRGE-induced angiogenic process requires the activation of PI3K/Akt-dependent MEK/ERK and eNOS/NO, which function as important signal mediators in its angiogenic signaling pathway. Fig. 3 . KRGE Does Not Increase the Expression of VEGF in HUVECs (A) HUVECs were incubated with or without KRGE (500 mg/ml) or TNF-a (10 ng/ml) for the indicated time periods. Total RNA was isolated, and RT-PCR was performed as described under Material and Methods. (B) Cells were incubated with or without VEGF (10 ng/ml) or KRGE (500 mg/ml) following pretreatment with a neutralizing VEGF antibody (VEGF nAb, 1 mg/ml) for 1h and allowed to proliferate for 48 h. Cell proliferation was determined by MTT assay. Data are expressed as the meanϮS.E. (nϭ3). * pϽ0.01 versus control; # pϽ0.01 versus VEGF alone. Fig. 4 . KRGE Stimulates the Activation of ERK1/2, Akt, and eNOS and NO Production in HUVECs (A) HUVECs were treated with 500 mg/ml of KRGE for 20 min or the indicated time periods. The levels of phosphorylated and total ERK1/2 were determined by Western blot analysis. (B) Cells were stimulated with KRGE (500 mg/ml) for the indicated time periods, and the levels of phosphorylated and total Akt and eNOS were determined by Western blot analysis. (C) Cells were treated with KRGE (500 mg/ml) for 4 h following pretreatment with 1 mM NMA for 30 min. Cells were then treated with 5 mM DAF-FM diacetate for 1 h at 37°C. The fluorescence images were captured using a confocal laser microscope. The relative levels of intracellular NO were calculated from the fluorescence intensity. Data are expressed as the meanϮS.E. (nՆ3). * and # pϽ0.01 versus control and KRGE, respectively.
DISCUSSION
Panax ginseng has been used in traditional oriental herbal medicine for its wide spectrum medicinal effects such as tonic, immunomodulatory, anti-cancer activity, adaptogenic and anti-aging activity, and antioxidant and neuroprotective properties. 12, 13, 22, 23) The major active components of ginseng are ginsenosides. More than forty ginsenosides have, so far, been isolated and each ginsenoside possesses different pharmacological effects. 22, 24) Commercially available Korean ginseng products are classified into fresh ginseng, white ginseng, and red ginseng. Although both Korean red and white ginseng products are manufactured from the same 6-year-old fresh ginseng roots, Korean red ginseng has higher contents of ginsenosides such as Rg3, Rg5 and Rh2 than white ginseng, 23) and its extract exhibits significantly higher pharmacological effects on vascular regeneration. 14) Ambiguously, some pure ginsenosides including Rg1 and Re have been shown to increase angiogenesis, 13) which contributes to the promotion of wound healing, 11) while others, such as Rg3, Rb1, and Rb2, showed a suppressive effect on VEGF-induced in vitro and in vivo angiogenesis 13) and inhibited tumor growth.
12) Since whole ginseng powder or ginseng extract are extensively used as alternative medicine in Asian and Western countries, we investigated the effects of KRGE on in vitro and in vivo angiogenesis. KRGE stimulated proliferation, migration, and tube formation in primary cultured HUVECs and angiogenesis in the animal model. Our results suggest that KRGE can be utilized as a potential therapeutic herbal medicine for several angiogenesis-related human diseases.
Angiogenesis requires the coordination or cross-talk between multiple signal transduction cascades, which are mainly known to be the PI3K/Akt, MAPK, and eNOS/NO signal pathways. The activation of PI3K/Akt stimulates eNOS activation by phosphorylation at serine 1177, leading to the elevation of NO production. 19, 20) Inhibition of the PI3K/Akt pathway or eNOS activity inhibits growth factorand cytokine-mediated angiogenesis, 19) indicating that activation of the PI3K/Akt/eNOS signal pathway is an important event in angiogenesis. Indeed, it has been shown that angiogenesis was significantly reduced in response to growth factors in eNOS-deficient mice, as determined by ex vivo aortic ring spouting and in vivo Matrigel assays, compared with wild type mice. 25) In addition, several lines of evidence have directly demonstrated that NO is a powerful angiogenic downstream mediator in the angiogenic response of a variety of growth factors 26) and that NO promotes endothelial cell proliferation, migration, and capillary morphogenesis in a cGMP-dependent manner. 20) In this study, KRGE stimulated endothelial cell proliferation, migration and tube formation as well as phosphorylation-dependent activation of Akt and eNOS, resulting in the elevation of NO production. Inhibition of the activation and/or activity of Akt and eNOS by wortmannin and NMA significantly suppressed KRGE-induced in vitro angiogenesis. These in vivo and in vitro findings provide definitive evidence that the PI3K/Akt/eNOS pathway plays an important role in KRGE-stimulated angiogenesis.
Angiogenic inducers such as VEGF 27) and fractalkine 19) stimulate the MAPK pathway, which is though to regulate cell growth, differentiation, survival, and death. Currently, three mammalian cytoplasmic MAPK pathways have been characterized in detail. Of these, the ERK1/2 pathway is predominately activated by growth factors, whereas the JNK/SAPK and p38 signal pathways are mainly activated by inflammatory cytokines and stress stimuli. The activation of the MEK-dependent ERK pathway plays an important role in endothelial cell migration and proliferation. Our previous study showed that the suppression of ERK1/2 phosphorylation inhibited both VEGF-and fractalkine-induced angiogenesis. 19, 28) This study demonstrated that KRGE induced angiogenesis via activation of the MEK/ERK1/2 pathway. Selectively blocking ERK1/2 using the MEK inhibitor PD98059 abrogates KRGE-induced endothelial cell proliferation, migration, and tube formation. These results suggest that MEKdependent ERK1/2 phosphorylation is also a critical signal event in KRGE-induced angiogenesis.
Signal transduction induced by angiogenic factors is known to involve both the PI3K/Akt and MEK/ERK1/2 pathways. 19) In some systems, these processes were found to be independently activated and equally important for angiogenic activity, 29) whereas in others, PI3K or ERK signaling played more dominant roles. 30) Our data showed that KRGE activated the MEK/ERK1/2, PI3K/Akt, and eNOS/NOS pathways, which were critically involved in its angiogenic activity. Inhibition of PI3K activity by wortmannin completely blocked the KRGE-induced phosphorylation of Akt, ERK1/2, and eNOS. The MEK inhibitor PD98059 inhibited only ERK1/2 phosphorylation without affecting Akt and eNOS phosphorylation. This result suggests that PI3K/Akt lies upstream and activates both ERK1/2 and eNOS. In addition, inhibition of eNOS activity by NMA partially sup- pressed ERK1/2 phosphorylation, suggesting that NO regulates ERK1/2 phosphorylation, probably by activation of cGMP-dependent protein kinase (PKG). Indeed, NO elevates the intracellular level of cGMP by activating soluble guanylate cyclase, resulting in the activation of PKG which activates ERK1/2. 31) These results suggest that KRGE activates the PI3K/Akt-dependent MEK/ERK1/2 and eNOS/NO signal pathways by sequential activation and cross-talk between the major signal components MEK/ERK1/2 and eNOS/NO for its full angiogenic activity.
Our findings demonstrate that KRGE induces angiogenesis by sequential activation of PI3K/Akt-dependent MEK/ ERK1/2 and eNOS/NO pathways and cross-talk between them for its maximum angiogenic activity in both the in vitro endothelial cell culture condition and the in vivo animal model. These results indicate that KRGE can be implicated in potential angiogenic therapy for improving cardiovascular and ischemic diseases, tissue repair, and wound healing.
